Thomas D. Reed, PhD
Dr. Reed is the Co-Founder of Triple-Gene as well as the Founder and CSO of Intrexon Corporation. During his 20+ year tenure at Intrexon, Dr. Reed has contributed to the invention and/or acquisition of numerous advanced technologies designed to improve the safety and efficacy of gene and cell therapies, which are the subject matter of numerous US and international patents. Within the last ten years, Dr. Reed has contributed to the design of oncology, cardiovascular, and rare disease therapies now advancing in the clinic. Prior to starting Intrexon, Dr. Reed’s scientific training focused on characterizing the structure and function of genes contributing to cardiovascular development and pathophysiology.
While members of the Medical Advisory Board are consulted to provide third party expert medical input into Triple-Gene’s product development efforts and clinical trial activities, they do not dictate or direct, nor are they responsible for, any development or clinical activities ultimately undertaken by Triple-Gene.